Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Early Zoom Investor had eyes on another Company #RGC
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO and had seen heavy sell off during period of mid June, however is seen bounced around 40% since the lows in June.
Of course one of the biggest and strongest supporter of the company share is no other than the company ) who believes in a better and brighter future for the company.
The founder and company CEO, (Mr Yat-Gai Au) in supporting of his commitment,confidence and his position towards the company, he has deployed over $5 million dollars of his own personel reservers in buying back company stock to reposition against possible short and distort sellers.
Another prominent early investor of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Movement in Healthcare Company Stock Price #RGC
The Fed is raising interest rates aggressively in an attempt to tame raging inflation and this has been hurting many stock investors who’s seeing bleeding portfolios on their phone or desktops.
Companies are predicted to slash forecasted earnings in the coming earnings quarter due to the high inflation rates and possible slowdown in earnings.
In an interview with MoneyWise earlier this year, Investor Rick Rule said, “I do not believe that the broad equities market will handle multiple rate hikes.”
Rule doesn’t suggest bailing on stocks completely.
This brings to a healthcare stock which had been recently IPO last year July 22’ which had seen a a good run of 300% capital gains after listing. Shares have taken a heavy hit from short sellers and hedge funds whom had strategically targetting the company stock. However RGC had recovered to the $30s, encouraged by study results for Regencell’s RGC-COV19 Traditional Chinese Medicine (TCM) formula for treating COVID-19 symptoms, frequent shareholder communication, and support for the shares in the market.
The formulae candidates aim to address the fundamental causes of disorders while alleviating symptoms and improving overall health at the same time. Taking a holistic approach, RGC’s TCM uses natural ingredients to treat different elements in the body and every bodily function is taken into consideration when preparing the TCM formulae for patients.
Unlike some early-stage companies, where it can be difficult to parse the many ways in which founders and executives may benefit whether or not the company succeeds, RGC has taken a more transparent approach that is well-aligned with shareholders’ long-term interests.
Some highlights about the company executives and founders, showing long term conviction in the company:
- CEO to draw only $1 annual salary and no bonus until the company reaches a $1 billion market capitalization
- CEO to continue company share buyback to demonstrate commitment to the Company and position against short and distort sellers.
- All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
In the next few months, RGC expects to report data from its second clinical study of its standardized TCM formula for the treatment of ASD and ADHD.
We will then findout if the company has been making positve progress on the company when the report becomes available.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
This Stock has similarities to HKD. Read me!
Regencell Bioscience (NASDAQ:[RGC]) is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital NYSE:[HKD], a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Comparison between the 2 companies can be found in the shared link below.
[https://www.benzinga.com/amp/content/28316977]
Daily short volume (%) refers to the number of shares that have been shorted as compared to the total daily volume traded.
RGC and HKD have much similar to share, but only time will tell if their share price would reflect the same.
Who is RGC's CEO and his achievements
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
Education Background and Achievements RGC CEO
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Hagemeyer, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors
[https://www.topionetworks.com/people/yat-gai-au-60866c12843bac2b60498b52]
Sharing Letter from the CEO of Regencell Bioscience (RGC)
The CEO of RGC has written a letter, thanking supporters and reason for pursuing forward.
Content of letter can be seen in RGC CEO's Twitter.
Thanks for your support! pic.twitter.com/OEL7M8a4y9
— Yat-Gai Au (@yat_gai) July 27, 2022
Similarities of HKD and RGC!!! TRENDING STOCK
Regencell Bioscience (NASDAQ:[RGC]). RGC is the top performing stock of all 2021 IPOs. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
[A June 2022 article](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i) mentioned that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital (NYSE:[HKD](https://www.benzinga.com/stock/HKD#NYSE)), a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Similaries in graphical table of these 2 companies can be seen in the link at end of article.
Daily short volume (%) refers to the number of shares that have been shorted as compared to the total daily volume traded.
[https://www.benzinga.com/amp/content/28316977]
Top 2021 performing IPO Stock with 237% returns! #RGC!! #HKD
The year 2021 was the busiest year for deals since 2000, with 1,035 listed companies in the United States. Biotech and Healthcare sectors took an overwhealming portion of 36% of the total IPO listed.
While it is not the strategy for most investors to target IPO shares, it is a surprise that the top performing IPO counter is a company with does not turn heads when mentioned. (ie. not a household name or famous company).
Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to [stockanalysis.com/ipos/2021/]. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
An article published in June 2022 has covered that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
Some key foundation points from the company,
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
https://www.benzinga.com/amp/content/28316977
$RGC might be the next $HKD Pump!
There are similarities between these 2 companies.
1. They both have high insider ownership >80%
2. Both have low float
3. Both companies are established in Hong Kong.
4. Both are the Top IPO companies in 2021 and 2022 (as of writing HKD is still the top)
List down more if you know!
#RGC could be the next #HKD! See the similarities!
Regencell Bioscience NASDAQ:[RGC] is the top performing stock of all 2021 IPOs according to stockanalysis.com/ipos/2021/. As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
For year 2022, the company which shot to the moon since IPO is AMTD Digital NYSE:[HKD], a company founded by Mr. Li Ka-Shing’s Cheung Kong Group and Hutchison Whampoa in 2003. HKD’s IPO price was $7.80 and has gained over a staggering 9,000% since, closing at $742.00 on August 1, 2022.
Although RGC is the #1 performer of 2021 IPOs, this pales in comparison with the current performance of HKD. Astute traders who have an eye for forensic analysis in companies with low float and outsized short interest are indeed very happy.
Daily short volume (%) refers to the number of shares that have been shorted as compared to the total daily volume traded.
Only time will tell if RGC will be the next pump after HKD but the similarities are there!
(https://www.benzinga.com/amp/content/28316977)
**4 Small Drug Stocks to Keep an Eye On**
Assertio Holdings: This Lake Forest, IL-based specialty pharma company, which markets neurology, inflammation and pain medications.
Earnings estimates for 2022 have improved from 35 cents per share to 40 cents per share over the past 60 days. The stock has risen 50% this year so far.
Assertio Holdings has undergone a major transformation. Its restructuring is now complete and the company has now shifted focus on growing its business. Assertio Holdings has invested in digital capabilities, resolved several legacy legal uncertainties and set up a new commercial model. The company’s successful execution of its restructuring plan has resulted in significant cost savings, which have boosted its profits despite product sales decline. The company raised its full-year adjusted EBITDA guidance in May, following strong first-quarter results and an optimistic outlook for the rest of the year.
Chinook Therapeutics: This Berkeley, CA-based biotech makes precision medicines for kidney diseases. The stock is up 12.3% this year so far.
Chinook Therapeutics’ lead clinical programs are atrasentan and BION-1301, which are being developed for IgA nephropathy (IgAN), a serious progressive disease. Data presented from the ongoing phase I/II study of BION-1301 in patients with IgAN have demonstrated durable reductions in mechanistic biomarkers and corresponding proteinuria reduction within three months of initiating treatment. Moreover, Chinook Therapeutics believes that atrasentan, which is in phase III development for IgAN, has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Both the candidates have been granted orphan drug designation by the European Commission for IgAN.
Regencell Bioscience: Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
For over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH effacacy trial (EARTH-A TRIAL) showned promising results which showned mild-moderate symtomps eliminated (except for Sensory Dysfunctional or occasional cough) on 97.3% of patients tested of the 37 patients gathered. EARTH-A TRIAL was conducted with the DELTA Variant.
Additional effecacy trial (EARTH-B TRIAL) was also conducted later, followed the same procedures as its predecessor effecacy trial but on a larger scale patient scale. In this trial, 80% of the COVID-19 caeses were of Omicron variant for patients gathered in Malaysia.
Viracta Therapeutics: CA-based Viracta Therapeutics is a precision oncology company targeting virus-associated malignancies. Its lead pipeline candidate is Nana-val, an all-oral combination of the proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is being evaluated in multiple clinical studies in cancers/solid tumors including a pivotal study for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma. Clinical data from some cohorts of the pivotal study as well as some other studies are expected later this year and could act as potential catalysts for the stock.
https://www.zacks.com/commentary/1948448/4-small-stocks-to-bet-on-in-an-upbeat-drugs-industry?cid=EC-Profit_from_the_Pros-20220707-FC02-A
Low float Company - Shortsqueeze in Action
Regencell Bioscience Limited’s (NASDAQ:RGC) is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The company has seen a good rise of over 300% since taking the company IPO in July 2021, and have seen on a roller coaster ride between euphoria and depression in the recent months.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
(https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/)
Information on latest short volumes can be taken from (https://fintel.io/ss/us/rgc#)
#RGC was top performing IPO Stock in 2021 with 237% from IPO day
The year 2021 was the busiest year for deals since 2000, with over a thousand (1035 nos) listed companies in the United States. Biotech and Healthcare sectors took an overwhealming portion of 36% of the total IPO listed.
While it is not the strategy for most investors to target IPO shares, it is a surprise that the top performing IPO counter is a company with does not turn heads when mentioned. (ie. not a household name or famous company).
Regencell Bioscience (NASDAQ:RGC). RGC is the top performing stock of all 2021 IPOs according to (http://stockanalysis.com/ipos/2021/). As of August 1, 2022, RGC is still ranked #1 with a 237% return above its IPO price of $9.50.
An article published in June 2022 has covered that RGC’s total cumulative short volume is over 19 million shares. While the stock has suffered from short sellers’ attacks since its listing, RGC has performed well. RGC has approximately 2.6 million tradable ordinary shares in the market and has maintained a low float as the founder and CEO has repeatedly purchased RGC ordinary shares from the open market.
Some key foundation points from the company,
As mentioned above, RGC is closely held by the CEO who owns over 81% of the company. He has used $5.9 million of his personal funds to purchase RGC shares from the open market since its IPO.
His consistent share purchases convey his confidence, commitment and conviction in the company and is putting his money where his mouth is. There are few companies that have the CEO owning this much of the business. The company’s entire management team has also extended the lock-up period of their share options, which shows they are collectively committed to their goal and mission, which is to save and improve lives.
https://www.benzinga.com/amp/content/28316977
Stocks fall after Walmart profit warning. Consider diversifying to weather the storm
U.S. stocks extended losses at Tuesday's open as investors mulled disappointing earnings from Walmart and General Motors and braced for results from Big Tech due out after the bell.
The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.
The International Monetary Fund further downgraded its forecast for global growth this year and warned of a "gloomy and more uncertain" amid worse-than-expected inflation.
The market sentiments now is filled with uncertainty as investors had thought that the dip had bottomed from the past weeks bounce. Certainly, this was not the case as we’ve seen recently in the past few days.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
A little background on the CEO, its investors and stock-option plan which we know so far,
- Chairman and CEO support
? Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. (whom is also a practitioner of TCM)
?Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
? Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
? Will not award share options for himself;
? Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased [49,010 shares](https://www.sec.gov/Archives/edgar/data/0001829667/000121390022026630/ea160018-13da4regen_regen.htm) (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
- Billionaire investor backing
Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.
- Stock option lock-up extended
All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx]
(NASDAQ:RGC) Insiders Percentage and they have not stop buying
In investing, it is always worth while to findout who are the majority shareholders of the company. Understanding of business ownership strucutre is vital as it determines who is in control of the company and its direction. Moreso, having a large number of shares would either benefit or loses most when the stock price moves.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
[For Image of Chart/Graph, kindly refer to the link at end of post]
Small companies that are not very actively traded often, thus lack institutional investors. It is more common to see insitutional investors in larger companies instead.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away.
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, it’s glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
[https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav]
Long Term Opinion, Buy Now, Ignore the Pain, Thank yourself 10 Years later.
How bad is the mood out there right now? Try max bearish.
So said Bank of America’s latest fund manager survey on Tuesday that showed expectations for profits and growth at recessionary levels. Yet Wall Street rallied partly on earnings optimism but also as some see all this gloom as a contrarian buying signal. Wednesday’s action is looking a bit more choppy.
It isn’t unimaginable that investors are overwhelmed right now, as they try to gauge whether central banks will tip economies into recession in a battle to control inflation. That’s not to mention the potential spillover from an economic downturn into corporate earnings.
Our call of the day from Bernstein analysts Mark Diver and Sarah McCarthy says investors are facing a short-term-pain-for-long-term-gain moment for stocks.
“Our longer horizon equity market sentiment indicators are providing significant sentiment support and point to strong positive global equity market returns over the next 12 months. Conversely, our shorter term sentiment indicator which is effective over a four-week period is only at neutral levels,” said the pair.
The divergence between those two suggests strong returns are possible for investors from current levels over a period of a year or more, but further downside in the short term before a tactical capitulation level is reached, said Diver and McCarthy.
[https://www.marketwatch.com/story/short-term-pain-for-long-term-gains-investors-need-to-settle-in-for-the-long-haul-says-bernstein-11658315400?siteid=yhoof2]
Im already invested in companies which are of moonshots and also fundamental ones.
Current deployment for stocks are 90% in fundamental and 10% for potential moonshots. Tho the majority of my gains were wiped out in the current bear, Im confident that I will thank myself for staying invested now.
Fundamental Long term : Tesla, Disney and Palantir.
Moonshots : Regencell Bioscience and Redbox (Which is kind of in hurt right now)
$RGC’s Company Ownership Insight
Understanding and looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders.
A high insider ownership often makes company leadership more mindful of shareholder interests. Small Cap stock, **Regencell Bioscience Holdings** (RGC) insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders. (A positive indication)
We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Regencell Bioscience Holdings.
This counter is worth to put on your watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Regencell Bioscience Holdings.
Yat-Gai Au, Founder of the company, who spent a stonking US$1.2m on stock at an average price of US$25.23.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Yat-Gai Au purchased 68.34k shares over the year. The average price per share was US$26.03.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html](https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html)
ShortSqueeze Play on this company with Low Float
Fellow redditors of r/wallstreetbets took Wall Street by storm when they rally against hedgefunds and showing the high and mightly folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankrupcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
Moreso, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggresive or awared traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Positive Outcome using TCM to Treat Covid-19 Patients
A Company in Hong Kong has been in the bioscience medical front, R&D-ing treatments of COVID-19 by using Traditional Chinese Medicine (”TCM”). This company is no other than Regencell Bioscience Limited $RGC which was founded in Year 2014 and recently IPO-ed in United States Nasdaq Market in Year 2021.
For over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach (EARTH) efficacy trial in Malaysia and the United States.
The first EARTH effacacy trial (EARTH-A TRIAL) showned promising results which showned mild-moderate symtomps eliminated (except for Sensory Dysfunctional or occasional cough) on 97.3% of patients tested of the 37 patients gathered. EARTH-A TRIAL was conducted with the DELTA Variant.
Additional effecacy trial (EARTH-B TRIAL) was also conducted later, followed the same procedures as its predecessor effecacy trial but on a larger scale patient scale. In this trial, 80% of the COVID-19 cases were of Omicron variant for patients gathered in Malaysia.
Of the 51 Patients tested during EARTH-B Trial, 94.1% of the patients (48 patients) had sympstoms of mild-moderated eliminated (except for Sensory Dysfunction or occasional cough) within 6 days; whereas 90.2% (46 patients) had reported recovery of one or more symptons after one day of treatment. This report showned significant responses to the treatment compared to EARTH-A Trials.
In short, majority of the patients were reported to have eliminated all symptons (except Sensory Dysfunctional and Occasional Cough) after 3.6 days of starting treatment.
[https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html](https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html)
$RGC Education Background and Achievements RGC CEO
Mr. Yat-Gai Au is the founder and CEO of Regencell. He graduated with a bachelor’s degree from UC Berkeley’s Haas School of Business and began his career in investment banking at Deutsche Bank and ING Barings.
Education Background and Achievements RGC CEO
Some of his accomplishments in his banking career were completed over US$4 billion worth of deals and won many prestigious M&A awards. Notable deals include the US$750 million acquisition of Philippine Long Distance Telephone, the US$650 million acquisition of Indofood and the US$1.8 billion secondary placement for 40% interest in Hagemeyer, all of which were executed on behalf of First Pacific Company Limited. He is also a founding partner of one of California’s largest group of property investors and an active technology and biotech investor.
Over the years, Yat-Gai has personally seen the amazing recovery of many ADHD and ASD patients using a particular Traditional Chinese Medicine treatment.
He established Regencell in 2015, after witnessing notable improvements in many cases, including close family members who had shown ADHD and ASD symptoms. Yat-Gai is now dedicating his professional efforts and personal funds to bringing the natural formula to patients, families and caregivers around the globe.
Mr Au personnel involvement in his own philanthropic project aims to provide care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties.
As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
Yat-Gai is passionate about participating in and funding charitable activities for the elderly, gifted students and the financially underprivileged in Hong Kong and USA. During the 2020 COVID19 outbreak, he has donated over 200,000 masks to hospitals, elderlies and needy families. In September 2018, Mr. Au setup Regencell Foundation Limited to further his charitable endeavors
[https://www.topionetworks.com/people/yat-gai-au-60866c12843bac2b60498b52]
The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.
The International Monetary Fund further downgraded its forecast for global growth this year and warned of a "gloomy and more uncertain" amid worse-than-expected inflation.
The market sentiments now is filled with uncertainty as investors had thought that the dip had bottomed from the past weeks bounce. Certainly, this was not the case as we’ve seen recently in the past few days.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
A little background on the CEO, its investors and stock-option plan which we know so far,
- **Chairman and CEO support.**
? Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. (whom is also a practitioner of TCM)
?Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
? Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
? Will not award share options for himself;
? Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased [49,010 shares](https://www.sec.gov/Archives/edgar/data/0001829667/000121390022026630/ea160018-13da4regen_regen.htm) (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
- **Billionaire investor backing.** Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.
- **Stock option lock-up extended.** All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
*As of writing today, the stock has gotten up 2%, July 26th 2022*
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
List of Companies which worked and are working on treating Covid.
There are a number of small companies are working on long Covid treatments.
More than four in survey of 10 people said that they knew someone with long Covid, a condition where symptoms persist for several weeks or longer. (Personally, 3 people i knew got covid in the same week out of the blue)
Long Covid is particularly complicated because there's no set list of symptoms. The Centers for Disease Control and Prevention notes a wide array of ongoing health problems that could include fatigue, shortness of breath, neurological and digestive symptoms as well as joint or muscle pain.
But so far, large companies are shying away from treating the condition.
Instead, small companies have taken up the mantle in long Covid treatment. They include Axcella Therapeutics (AXLA), First Wave BioPharma (FWBI), Ampio Pharmaceuticals (AMPE), Regencell Bioscience (RGC), Aim ImmunoTech (AIM), Tonix Pharmaceuticals (TNXP) and privately held Humanetics.
Hong Kong-based Regencell Bioscience is an early clinical stage bioscience company, founded in 2014, is in the business of using traditional Chinese medicine (”TCM”) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases which affects the immune system such as COVID-19.
The company’s formula aims to treat the core causes of disoders while reducing the symptoms and improving overall health of its patients at the same time. The direction of using natural ingredients (herbs) to treat elements in the body is taken as the company’s hoistic approach toward the treamtent process while preparing the TCM formulae for its patients.
[https://www.investors.com/news/technology/long-covid-treatments-here-are-the-penny-stocks-working-on-this-growing-problem/]
Short Squeeze Stock like GME on Healthcare Counter
Redditors of wallstreetbets took Wall Street by storm when they rally against hedgefunds and showing the high and mightly folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankrupcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
Moreso, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggresive or awared traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i](https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i)
Non-Stop Insider Shares Buyback!
In investing, it is always worth while to findout who are the majority shareholders of the company. Understanding of business ownership strucutre is vital as it determines who is in control of the company and its direction. Moreso, having a large number of shares would either benefit or loses most when the stock price moves.
Data shows that insiders recently bought shares in the company and they were rewarded after market cap rose US$64m last week.
Small companies that are not very actively traded often, thus lack institutional investors. It is more common to see insitutional investors in larger companies instead.
There are multiple explanations for why institutions don't own a stock. The most common is that the company is too small relative to funds under management, so the institution does not bother to look closely at the company. Alternatively, there might be something about the company that has kept institutional investors away.
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, it’s glad to see a company insider with such skin in the game. In comparison, the second and third largest shareholders hold about 7.6% and 0.1% of the stock.
With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Regencell Bioscience Holdings. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
With a stake of 7.6%, private equity firms could influence the Regencell Bioscience Holdings board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
[https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav]
This stock has comparable ShortSqueeze Play to GME!
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/](https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/)
Promising Treatment Outcome for COV19 in RGC's report!
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
RGC was listed on July 21’ and has seen a rocket rise in share price over 300% weeks after its listing.
Based on BioSpectrum, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
In latest findings, for over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH effacacy trial (EARTH-A TRIAL) showned promising results which showned mild-moderate symtomps eliminated (except for Sensory Dysfunctional or occasional cough) on 97.3% of patients tested of the 37 patients gathered. EARTH-A TRIAL was conducted with the DELTA Variant.
Additional effecacy trial (EARTH-B TRIAL) was also conducted later, followed the same procedures as its predecessor effecacy trial but on a larger scale patient scale. In this trial, 80% of the COVID-19 cases were of Omicron variant for patients gathered in Malaysia.
Of the 51 Patients tested during EARTH-B Trial, 94.1% of the patients (48 patients) had sympstoms of mild-moderated eliminated (except for Sensory Dysfunction or occasional cough) within 6 days; whereas 90.2% (46 patients) had reported recovery of one or more symptons after one day of treatment. This report showned significant responses to the treatment compared to EARTH-A Trials.
In short, majority of the patients were reported to have eliminated all symptons (except Sensory Dysfunctional and Occasional Cough) after 3.6 days of starting treatment.
[https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html](https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html)
$RGC CEO Letter to Shareholders
Dear Shareholders:
As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond.
For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”).
We have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. We aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. We are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
Research Studies
Our first study using personalized TCM formula in Hong Kong showed a drop in assessment scores meaning that ADHD and ASD symptoms were less severe for patient who participated in the study. However, there is no assurance that we can expect similar outcome in our second research study.
Encouraged by this positive outcome, we plan to commence our second research study next month in Hong Kong, which is expected to last for approximately one year. Approximately 100 patients will participate in our second research study, in 3-12 months treatment cycles. Our goal for the second research study is to verify the effectiveness of the standardized TCM formulae with candidates that are experiencing mild, moderate and severe ADHD and ASD conditions. Once completed, the research study will provide the foundation for the Company to apply for a proprietary Chinese medicine (“pCm”) registration in Hong Kong. We look forward to sharing the outcome as soon as we complete the study.
During a short period of time, we have achieved significant milestones, and these could not have been achieved without the tremendous backing of our long-time supporters. Speaking on behalf of our entire management team and board of directors, I would like to extend my thanks and deepest gratitude to:
Mr. Samuel Chen and Mrs. Fiona Chen, Dr. Hai Ping Jin and Mr. Jay Lee for their contribution and support to our research. Their investment gives hope to ADHD and ASD patients, their families and caregivers in need of a solution.
Also, Mr. Sik-Kee Au, our strategic TCM research partner, for offering his 30+ years of experience in TCM research & development, and clinical practice. Our partnership with Mr. Au has been instrumental in conducting our studies and has given us the exclusive rights and ownership of all his TCM formulae and the intellectual property rights of the TCM formulae.
Last but not least, I would like to thank all of our business partners, professionals and investors for making this possible, and to our team for the amazing work they continue to do every day.
[https://www.businesswire.com/news/home/20210805005564/en/Regencell-Bioscience-Holdings-Limited-Releases-CEO-Letter-to-Shareholders]
$RGC CEO Letter to Shareholders
Dear Shareholders:
As CEO of Regencell, I am pleased to take this opportunity to discuss the significant milestones we achieved thus far in 2021, update our shareholders on our business plan for the remainder of the year and discuss our goals for 2022 and beyond.
For those who are new to Regencell, the Company focuses on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”).
We have been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. Our goal is to improve the lives of ADHD and ASD patients, their families and caregivers and become a market leader for the treatment of these disorders. We aim to achieve improvements in both symptoms and overall health of patients as compared to currently available medications in the market. We are passionate about transforming the lives of patients, their families and caregivers and help them feel their best physically, mentally and emotionally!
Research Studies
Our first study using personalized TCM formula in Hong Kong showed a drop in assessment scores meaning that ADHD and ASD symptoms were less severe for patient who participated in the study. However, there is no assurance that we can expect similar outcome in our second research study.
Encouraged by this positive outcome, we plan to commence our second research study next month in Hong Kong, which is expected to last for approximately one year. Approximately 100 patients will participate in our second research study, in 3-12 months treatment cycles. Our goal for the second research study is to verify the effectiveness of the standardized TCM formulae with candidates that are experiencing mild, moderate and severe ADHD and ASD conditions. Once completed, the research study will provide the foundation for the Company to apply for a proprietary Chinese medicine (“pCm”) registration in Hong Kong. We look forward to sharing the outcome as soon as we complete the study.
During a short period of time, we have achieved significant milestones, and these could not have been achieved without the tremendous backing of our long-time supporters. Speaking on behalf of our entire management team and board of directors, I would like to extend my thanks and deepest gratitude to:
Mr. Samuel Chen and Mrs. Fiona Chen, Dr. Hai Ping Jin and Mr. Jay Lee for their contribution and support to our research. Their investment gives hope to ADHD and ASD patients, their families and caregivers in need of a solution.
Also, Mr. Sik-Kee Au, our strategic TCM research partner, for offering his 30+ years of experience in TCM research & development, and clinical practice. Our partnership with Mr. Au has been instrumental in conducting our studies and has given us the exclusive rights and ownership of all his TCM formulae and the intellectual property rights of the TCM formulae.
Last but not least, I would like to thank all of our business partners, professionals and investors for making this possible, and to our team for the amazing work they continue to do every day.
[https://www.businesswire.com/news/home/20210805005564/en/Regencell-Bioscience-Holdings-Limited-Releases-CEO-Letter-to-Shareholders]
Short Squeeze Potential Play on this Small Cap $RGC
Regencell Bioscience Limited’s (NASDAQ:RGC) stock that has seen a good rise of over 300% since taking the company IPO in July 2021. The company is a bioscience **healthcare** company that focuses on heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
Analyst has covered that RGC has a undiscovered short squeeze potential. Similarities are found between RGC and GameStop Corp. $GME, where both short volume ratio are over 40% in the past year, with periods where RGC is a more heavily shorted counter than GME (~90% shorted).
As of May 16th 2022, RGC’s Founder & CEO holds 81% of total issued and outstanding ordinary shares (10,539,159). RGC’s total cumulative short volume as reported by 3rd party data analytics is over 19 million shares. Moreover, the total reported short volume to outstanding shares (excluding CEO and chairman ownership ratio) is over 7 times, which is almost 2x of GME.
[https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/]
Consider this stock to weather the storm! Diversify into Healthcare! $RGC
U.S. stocks extended losses at Tuesday's open as investors mulled disappointing earnings from Walmart and General Motors and braced for results from Big Tech due out after the bell.
The benchmark S&P 500 tumbled 0.6%, while the Dow Jones Industrial Average declined by roughly 100 points, or 0.3%. The technology-heavy Nasdaq Composite fell 1.1%.
The International Monetary Fund further downgraded its forecast for global growth this year and warned of a "gloomy and more uncertain" amid worse-than-expected inflation.
The market sentiments now is filled with uncertainty as investors had thought that the dip had bottomed from the past weeks bounce. Certainly, this was not the case as we’ve seen recently in the past few days.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
A little background on the CEO, its investors and stock-option plan which we know so far,
*Chairman and CEO support*
Since RGC’s incorporation in October 2014 up to the IPO, the Company has been fully funded by its Chairman and CEO, Mr. Yat-Gai Au. (whom is also a practitioner of TCM)
Upon the IPO, the Chairman’s loan of USD $3.25 million, was converted into ~342,000 common shares at the initial offering price of USD $9.50.
Pledged to not draw salary and bonus of more than USD $1 until the Company reaches USD $1 billion market capitalization;
Will not award share options for himself;
Since the IPO, RGC’s Chairman and CEO has purchased over USD $5 million in common shares on the open market. Most recently, he purchased [49,010 shares](https://www.sec.gov/Archives/edgar/data/0001829667/000121390022026630/ea160018-13da4regen_regen.htm) (~ USD $1.1 million) between April 1 and May 16, 2022, bringing his ownership to 81% of outstanding shares (~10.5 million).
*Billionaire investor backing*
Samuel Chen, a successful early Zoom Video Communications (NASDAQ:ZM) investor is one of the major backers of RGC. Last reported 13G filing shows he holds a 7.63% stake in the company.
Stock option lock-up extended*
All directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx](https://scr.zacks.com/news/news-details/2022/RGC-CEO-Figuratively-Putting-His-Money-Where-His-Mouth-Is/default.aspx)
Company Treating COVID19 using Traditional Chinese Medicine Method (TCM) $RGC
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which had taken lives and destroyed familes. Recently, there have been surges of COV patient cases within the ASIA region according to today’s data.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC which has seen a rocket rise in share price over 300% weeks after its listing.
Based on BioSpectrum, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
In one of its findings, for over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH effacacy trial (EARTH-A TRIAL) showned promising results which showned mild-moderate symtomps eliminated (except for Sensory Dysfunctional or occasional cough) on 97.3% of patients tested of the 37 patients gathered. EARTH-A TRIAL was conducted with the DELTA Variant.
Additional effecacy trial (EARTH-B TRIAL) was also conducted later, followed the same procedures as its predecessor effecacy trial but on a larger scale patient scale. In this trial, 80% of the COVID-19 cases were of Omicron variant for patients gathered in Malaysia.
Of the 51 Patients tested during EARTH-B Trial, 94.1% of the patients (48 patients) had sympstoms of mild-moderated eliminated (except for Sensory Dysfunction or occasional cough) within 6 days; whereas 90.2% (46 patients) had reported recovery of one or more symptons after one day of treatment. This report showned significant responses to the treatment compared to EARTH-A Trials.
In short, majority of the patients were reported to have eliminated all symptons (except Sensory Dysfunctional and Occasional Cough) after 3.6 days of starting treatment.
[https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html]
Company CEO Buying Back Company Shares $RGC #BUYBACK
The company CEO of Regencell Bioscience Holding (RGC) has been buying back shares over the year. (over 68.34k shares with average price of $USD 26) which is not far from last night’s closing price at $USD 31.50. The company stock price dropped in this week’s lowest of $USD 31! becoming its new support line. (You could infact be buying this share at the same price as the CEO !!)
In fact, the company CEO (Mr Au) ‘s recent purchase of shares was the biggest made as an insider individual.
That means that an insider was happy to buy shares at above the current price. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares.
As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Yat-Gai Au was the only individual insider to buy shares in the last twelve months.
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests.
Regencell Bioscience Holdings insiders own 81% of the company, currently worth about US$260m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
[https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html](https://finance.yahoo.com/news/founder-regencell-bioscience-holdings-limited-101443485.html)
Short Squeeze Stock for your Watchlist (Hint: Its similar to GME)
A short squeeze is an uncommon condition that triggers rapidly rising prices in a stock due to short sellers being forced to cover their positions by buying shares. For a short squeeze to happen, the stockmust have significant number of short-sellers holding positions in it.
Short squeezes are arguably always a gamble. Experiences in the market has shown that, some stocks have moved higher after a heavy short interest, while in others they tank downwards.
The latest and reknown event of a short squeeze happened in January 2021, on $GME GameStop, which took the market by storm, causing major financial consequences for some hedge funds, large losses for short-sellers and even putting some funds on bankrupt.
Roughly 140% of the game retailer’s public float had been sold short. There was a mad rush to buy shares to cover those positions, which caused the price to rise further.
One counter that had been spotted on the radar is Regencell Bioscience Ltd ($RGC).
RGC’s short volume ratio has similar pattern to of $GME with an average of > 40% in the past year. Research has found that Regencell has instances been more heavily shorted than $GME. (Sometimes close to 90% shorted)
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
CHECK OUT THIS UNDERVALUED STOCK (MoonShot Potential) $RGC
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell has completed its first research study using personalized TCM formula for the treatment of ADHD and ASD in Hong Kong (where the company is located) and aims to launch three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
The company’s strategy will be to run the research locally in Hong Kong, and to subsequently expand its presence and threatment to other markets as part of their expansion strategy. In the company’s preparation for its future expansion, RGC has formed a JV (”joint venture”) to offer COVID-19 related treatments to patients in ASEAN countries, India, Japan, Australia and New Zealand.
The company CEO, Mr Au has shown deep conviction and believe in his company’s direction and mission. To cement his and the company’s mission, all directors and employees who were granted stock options during the company’s IPO (”Initial Public Offering”) have agreed to a lock-up for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
Moreso, Mr Au has declare that he will only receive $1 dollar annual salary and will receive no bonus until the company reaches $1 billion market capitalisation.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
$ZOOM investor had Eyes on this Company Stock $RGC
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (TCM) treatment specifically ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorders), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen >300% growth since IPO was consolidating between $20-$22 (Q2 22’) before its resistance breakout last month.
Of course one of the biggest and strongest supporter of the company share is no other than the company Founder and CEO (Mr Yat-Gai Au)) who believes in a better and brighter future for the company.
In supporting of his commitment,confidence and his position towards the company, he has deployed over $5 million dollars of his own personel reservers in buying back company stock to reposition against possible short and distort sellers.
Another prominent supporter of RGC is Mr Samuel Chen, who is a very succesful early **Zoom Video Communications, Inc.** investor (Nasdaq: Zoom). Mr Samuel owned 8.8% of Zoom shares and was the second largest individual investor.
To date, Mr. Au has converted his shareholders’ loan of $3.25 million to Regencell’s ordinary shares upon listing and has pledged not to draw a salary and bonus of more than $1 until Regencell reaches a $1 billion market capitalization and reserved share options for all employees except himself.
In addition, in demonstrating the management’s commitment towards the company, all all directors and employees who were previously granted stock options upon Regencell’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested. As their stock options are set to vest on July 16, 2022, their shares will remain locked up until January 16, 2023.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
$RGC High Conviction CEO and What he's doing next
Regencell Bioscience Holdings (RGC) a healthcare bioscience company which had been a topic of trend amongs traders and short sellers have seen its price taking a beating a few months after its IPO last year.
The CEO (Mr Au) has voiced out his concerns that these negative sentiments are not only hurting the company but also investors and patients who are seeking threatments.
RGC’s business model is focussing on using Traditional Chinse Medicine (TCM) to treat attention hyperactivity disorder (“ADHD”), autism spectrum disorder (“ASD”) and COVID-19-like ilnesses and these negative FUD (Fear, Uncertainty and Doubt) are obstacles to the company’s mission and goal.
These negative sentiments are strategies deployed by sophisticated hedge funds by using short selling and complex derivaties to take advantage of small investors.
In defense against these strategically ploy by these hedge funds, Mr Au has agreed to only draw $1 annual salary and no bonus until the company reaches a $1 billion market capitalization and reserve share options for all employees except himself.
Furthermore, Mr Au’s personal funds will be used to buyback company shares to demonstrate his commitment to the Company and to reposition against short and distort sellers. Based on publicly available data, the Company believes there is a total cumulative short volume of over 19 million shares since the Company’s IPO.
Mr Au “I began my share purchases since last year, using my personal funds in order to further our goal to save and improve lives.”
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo](https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo)
$RGC DEFENSIVE STOCK PLAY FOR YOUR WATCHLIST
Regencell Bioscience Holdings (RGC)'s CEO (Mr. Yat-Gai Au) has been buying RGC shares since 2021 at an average price of $26 a share — and now has over 80% ownership.
The company had a huge upward swing days after the IPO but was hit with short sellers following that. Even at volatile times, the company CEO has not sold a single share and its even backed by prominent investor Samuel Chen as one of the company's major backers.
(For context : Samuel Chen was a successful early Zoom Video Communications (Nasdaq: ZM) investor)
Despite being shorted heavily in the early months of Q2 22', the company stock has been on an upward trent despite the huge sell off in many markets sectors, predominantly in the growth stock and crypto market.
RGC could be a play by investors who wishes to diversify their porfolio into healthcare stock to reduce the downside risk of market volatility. RGC is still in their early stage of TMC trial and we look forward to positive results from their R&D for ADHD & ASD treatments.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
Healthcare Bioscience Company - Regencell $RGC holding against down times
The market sentiments now is filled with uncertainty, fear, confusion if the bear is over, while seeing rebounds of major company stock in an uptrend after, experiencinglarge drops of more than 50%. The negative contributions are due to inflationary and Consumer Price Index (CPI) numbers while contributed by the high price of oil >100$ right now.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialisation of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO was consolidating between $20-$22 before its resistance breakout in May 22” and shown a bullish pattern in recent weeks. The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th Janurary 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo](https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo)
$RGC - A Small Cap Bioscience Company - Treatment Findings and Company Mission and Goals
Regencell Bioscience Holdings ($RGC: Nasdaq) is a an early-staged bioscience healthcare company focusing on R&D and commercilisation of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations.
Regencell Bioscience’s formulation for the treatment of ASD and ADHD disorders was developed by Mr. Sik-Kee Au, a TCM practitioner of over 30 years and Company Founder, who has used the formula to treat patients with ASD and ADHD.
Currently, the Company is working towards standardization and commercialization of its formula.
The formula is based on “Sik-Kee Au TCM Brain Theory” hypothesis ) that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain.
For over a year (Mar 2020 - Aug 2021), RGC has established protocols and procedures for conducting Evaluation and Assessment of RGC-COV19 TCM through a Holistic approach **(EARTH)** efficacy trial in Malaysia and the United States.
The first EARTH effacacy trial (EARTH-A TRIAL) showned promising results which showned mild-moderate symtomps eliminated (except for Sensory Dysfunctional or occasional cough) on 97.3% of patients tested of the 37 patients gathered. EARTH-A TRIAL was conducted with the DELTA Variant.
Additional effecacy trial (EARTH-B TRIAL) was also conducted later, followed the same procedures as its predecessor effecacy trial but on a larger scale patient scale. In this trial, 80% of the COVID-19 caeses were of Omicron variant for patients gathered in Malaysia.
Readers who are interested in listening to the interview done by SSN Network, where RGC’s CEO Jay Lee and Independant Director, Paul Niewiadomski shares their story of the Company, TCM and also the results of TCM Treatments and Recent Efficacy Trial Results.
[https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html](https://finance.yahoo.com/news/rgc-second-investigational-study-rgc-094600752.html)
RGC’s company goal is “to be the global leader in the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of the coronavirus disease particularly COVID-19, for which there are unmet holistic medical needs in the global market.”
The company mission is short, simple yet powerful; "Our primary goal is to save lives” and they are planning on achieve the company mission through their deployment of TCM treatments to improve the betterment and also save lives of all people.
More information about the companys Goal, Mission, Management and Services can be found on their official website
[https://regencellasia.com/](https://regencellasia.com/)
$RGC - Company with low float, with potential like GME ShortSqueeze!
Community of r/wallstreetbets took Wall Street by storm when they rally against hedgefunds and showing the high and mightly folks in fancy suits who’s the boss by short squeezing $GME (GameStop) stock. The stock of GME reached a premarket value of over $500 per share. The price was nearly 30 times the $17.25 valuation at the beginning of January 2021; putting big losses to hedge funds and also sending some of them packing (filed for bankrupcy).
A similar potential is seen in $RGC Regencell Bioscience Holdings where the short volume ratio has a similar pattern to that of GameStop with both averaging over 40% in the past year.
Moreso, Regencell found to be shorted occasional days close to 90%, higher than GameStop.
Regencell’s total cumulative short volume, as reported by a third-party data analytics provider, is over 19 million shares, while the total outstanding shares less CEO and Chairman’s shares is only approximately 2.4 million, yet Regencell is still trading over 289% its IPO price.
Its total reported short volume to outstanding shares ratio (excluding CEO and Chairman’s shares ratio) is almost double of GameStop, being approximately 8 times whereas GameStop is slightly over 4 times. GameStop is currently trading 50x over its historical low of $2.52.
Little is known if there will be any short squeeze happening on RGC but it is something aggresive or awared traders could keep in their watchlist.
[https://www.benzinga.com/general/biotech/22/06/27567868/traders-may-keep-hunting-for-another-squeezable-stock-like-gamestop-how-does-this-tickers-short-i]
$RGC, a Company with huge upside. 300% Since IPO
Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder **(”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.
In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 petients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.
The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
The company’s current plan is to trade, manufacture, market and distrubte the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]